Janssen

Subsidiary of Johnson & Johnson (JNJ)

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
ProteasomeSmall molecule
Multiple MyelomaMantle Cell Lymphoma
Phase 1/2
TROP2Antibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
LCB84Phase 1/2Advanced Solid Tumors
Est. primary completion 2027-01 · NCT05941507 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 August 2026ApprovalustekinumabFDA approves Stelara for pediatric ulcerative colitis
US, FDA · Janssen · Source ↗
5 April 2024ApprovalCiltacabtagene autoleucelFDA approves CARVYKTI for earlier lines (CARTITUDE-4)
US, FDA · Janssen Biotech, Inc. · Source ↗

Financial reports

No financial reports recorded.